Strategic Advocates’s Cytokinetics CYTK Stock Holding History

Strategic Advocates’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$110	–	640
2025 Q3	$110	Buy	+2	New	+$82	﹤0.01%	574

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Strategic Advocates's CYTK Position: Q4 2025 in Review

Strategic Advocates sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 2 shares — an estimated $110 sold.

Strategic Advocates first reported a position in CYTK in Q3 2025 and held it in 1 quarter. The position peaked at $110 in Q3 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

Strategic Advocates reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
Strategic Advocates sold 2 Cytokinetics shares in Q4 2025, an estimated $110.
Strategic Advocates first reported a position in Cytokinetics in Q3 2025 and held it in 1 quarter.
Strategic Advocates's Cytokinetics position peaked at $110 in Q3 2025.
430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Strategic Advocates's 13F filing for Q4 2025, filed 11 Feb 2026.